Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or Behavior
Conditions
Interventions
Esketamine
Midazolam
+2 more
Locations
6
United States
Peachford Hospital-Atlanta Behavioral Research
Atlanta, Georgia, United States
University of Cincinnati
Cincinnati, Ohio, United States
Instituto Apice
Salvador, Brazil
Centro Integrado Facili
São Bernardo do Campo, Brazil
Taipei Veterans General Hospital
Taipei, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Start Date
January 8, 2026
Primary Completion Date
April 9, 2031
Completion Date
September 15, 2031
Last Updated
April 13, 2026
NCT05415397
NCT07059234
NCT06396312
NCT06136546
NCT06398496
NCT06417619
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions